Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 7686 results

  1. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493

    Awaiting development [GID-TA11639] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

    In development [GID-TA11602] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

    In development [GID-TA10999] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  7. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  8. Falls: assessment and prevention in older people and people 50 and over at higher risk (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 28 November 2024.

    NICE guideline
    In consultation

  9. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  10. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  12. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 09 January 2025

    Technology appraisal guidance
    Awaiting development

  14. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development